despit lower contribut pharmedium fundament core pharma
busi remain strong perform in-lin ahead expect fact
ex-pharmedium pharma adj oper incom guidanc remain notabl
think well posit growth due greater leverag greater
contribut pharmedium lower tax rate
pharma busi perform in-lin ahead expect
despit lower expect contribut pharmedium due voluntari
suspens oper memphi outsourc facil management note
core fundament pharma busi remain strong exclud lower
contribut pharmedium management pharma adj oper incom guidanc
remain notabl volum gener complianc custom renew sell-sid rate
margin perform expect better anticip gener deflat
remain stabl high-singl digit in-lin management expect
manag gener deflat drive greater gener complianc fact decreas
gener leakag percentag bp y/i management note brand
inflat track pretti much expect increas slightli better guidanc
assumpt furthermor specialti distribut busi legaci absg
grew revenu y/i consecut quarter greater revenu growth
posit growth view
think well posit growth due sever factor
estim y/i adj ep growth also includ greater share
greater leverag contribut store acquir fulli
ramp gain greater leverag recal asid impact
smith increas sg larg attribut open sixth new
distribut center despit fact still process transit
acquir store far servic mroe acquir store
greater pharmedium contribut lower contribut pharmedium
tailwind reduct contribut revers
lower tax rate realiz full benefit tax reform management
expect bp reduct effect tax rate compar
expect
updat estim price
rais adj ep estim
respect also rais price target base revis
dcf analysi impli share trade adj ep estim
current multipl
pleas see page report import disclosur
posit think on-going transit custom new
price model break specialti result margin expans drive growth
profit addit sourc benefit wbad help drive margin
profit medium-term volum esrx onboard onboard
store acquir also serv near-term tailwind
 transit acquir store
 top-lin growth driven specialti
includ alliancerx acquisit hd
smith store acquir
 gross margin
 ebit margin
 top-lin growth low-teen due
greater expect growth specialti
 gm due better
 sg better expect due
 share come lower due greater
expect share repo
 top-lin growth mid-singl digit
due slower slower onboard
store acquir lower brand
 margin closer due higher
expect gener deflat lower
 sg come wors expect
 share come higher due lower
one three largest pharmaceut distribut compani
 servic pharmaceut manufactur health care provid
pharmaceut suppli channel primarili provid drug distribut relat servic
distribut comprehens offer brand name gener pharmaceut over-the-
counter health care product home health care suppli equip wide varieti
health care provid locat throughout includ acut care hospit
health system independ chain retail pharmaci mail-ord facil physician
clinic altern site facil skill nurs assist live center
million except per share data
cowen compani
changevariancetot cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig net incom deal-rel incom ex-discontinu average ep ex-discontinu chang specialti chang chang basi earn basi chang basi earn basi cowen
million except per share data
cowen compani
model assumptionstermin growth depreci chang work capit valuefre free futur excess number per end septemb cowen
million except per share data
compani file cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig incom cont incom deal-rel incom ex-discontinu average ep ex discontinu chang incom cont ep cont end septemb cowen
million except per share data
compani file cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig net incom deal-rel incom ex-discontinu average ep ex-discontinu chang year-over-year total incom cont ep cont cowen
million
compani file cowen compani
chang basi earn basi chang basi earn basi cowen
million
compani file cowen compani
asset receiv net doubt expens current charg total liabil account payabl incom current equiti common paid-in earn comprehens commmon stock total stockhold liabil stockhold liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total interest ratio return commit capit asset averag stockhold equiti cowen
million
compani file cowen compani
income/ loss flow oper activ depreci provis loss account sale invest employe stock defer incom invest impair oper asset liabil account merchandis prepaid expens account payabl accru expens incom net cash oper acquisit properti acquisit purchas treasuri dividend common proceeds/ repay debt net increase/ decreas cash equival begin cash equival end summari oper year end septemb cowen
million
compani file cowen compani
activitiesnet incom discontinu incom continu reconcil net incom provis loss account provis defer incom employe stock loss dispos properti impair charg equiti invest -- -- -- lifo expens -- -- -- -- -- pension settlement -- -- -- -- -- includ intang asset loss earli retir debt -- -- -- -- loss sale discontinu op -- -- -- -- -- -- cumul effect account chang net -- -- -- -- -- -- chang oper asset liabil account merchandis prepaid expens account payabl accru expens incom cash provid use oper activ continu cash provid use oper activ discontinu cash provid use oper activitiescapit acquir compani net cash sale properti -- equiti invest -- -- -- sale-lease-back transact -- -- -- -- -- -- proce sale busi -- -- -- -- purchas invest secur avail sale -- -- -- -- sale invest secur -- -- -- -- -- -- -- -- -- -- cash provid use invest activ continu cash provid use invest activ discontinu -- -- net cash provid use invest activitiesborrow revolv securit credit facil -- -- -- -- -- -- proce borrow relat pmc distribut -- -- -- -- -- -- long-term debt borrow -- -- -- -- long-term debt repay -- -- -- -- purchas treasuri financ cost -- exercis warrant -- -- -- -- -- stock dividend common cap call option -- -- common stk purchas employe stock purchas plan net -- -- -- -- -- -- -- -- -- -- cash provid use financ activ continu cash provid use financ activ discontinu -- -- othernet cash provid use financ cash cash cash equival begin cash equival end year end septemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
potenti risk associ drug distribut space industri
highli competit could pressur margin core drug distribut busi
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind industri concern
around sustain high growth biotech sector longer term
impact ppaca expect increas volum could subdu depend
implement execut
number company-specif risk associ pt includ credibl
indic enter pharma suppli chain sharp unexpect declin
gener deflat less expect benefit wbad econodisc
